Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

Author(s): Andrew J. Armstrong, MD, ScM¹; Vinnie Y.T. Liu, MSc²; Ramprasaath R. Selvaraju, PhD²; Emmalyn Chen, PhD²; Jeffry P. Simko, MD, PhD³; Sandy DeVries, MA³; Oliver Sartor, MD⁴; Howard M. Sandler, MD⁵; Osama Mohamad, MD, PhD³; Huei-Chung Huang, MA²; Jacqueline Griffin, PhD²; Rikiya Yamashita, MD, PhD²; Andre Esteva, PhD²; Phuoc T. Tran, MD, PhD⁶; Daniel E. Spratt, MD⁷; John Hi Carson, MD⁸; Christopher Peters, MD⁹; Elizabeth Gore, MD^10,11; Steve P. Lee, MD, PhD¹²; Jedidiah M. Monson, MD¹³; Mark E. Augspurger, MD¹⁴; Ali El-Gayed, MD¹⁵; Joseph P. Rodgers, MS^16,17; Rana McKay, MD¹⁸; Todd Morgan, MD¹⁹; Felix Y. Feng, MD³; Paul L. Nguyen, MD²⁰;

Source: DOI: 10.1200/JCO.24.00365

Dr. Anjan Patel's Thoughts

A new MMAI-derived digital pathology biomarker was trained and prospectively validated across multiple NRG/RTOG phase III trials, including RTOG 9202 (N=1,192), to predict which high-risk/locally advanced PCa patients benefit from LT-ADT vs ST-ADT with RT. In the overall cohort, LT-ADT reduced DM (17% vs 26% at 15 years) and DDM (15% vs 23% at 15 years), but this benefit was limited to biomarker-positive patients (DM: 19% vs 33%; DDM: 19% vs 30%), with no advantage seen in biomarker-negative patients (DM: 11% vs 11%; DDM: 9% vs 10%). This tool could allow about a third of our "high-risk" patients to avoid two extra years of ADT without compromising metastasis outcomes, while ensuring we intensify for those most likely to benefit. In short, this is a practical step toward personalizing ADT duration and sparing toxicity for a significant subset of our patients.

PURPOSE

Long-term androgen deprivation therapy (ADT) improves survival in men with high-risk localized prostate cancer (PCa) receiving radiotherapy (RT). Predictive biomarkers are needed to guide ADT duration.

METHODS

A multimodal artificial intelligence (MMAI)???derived predictive biomarker was trained for long-term (LT) versus short-term (ST) ADT using pretreatment digital prostate biopsy images and clinical data (age, prostate-specific antigen, Gleason, and T stage) from six NRG Oncology phase III randomized radiotherapy trials. The novel MMAI-derived biomarker was developed to predict the differential benefit of LT-ADT on the primary end point, distant metastasis (DM). MMAI predictive utility was validated on a seventh randomized trial, RTOG 9202 (N = 1,192), which randomly assigned men to RT + ST-ADT (4 months) versus RT + LT-ADT (28 months). Fine-Gray and cumulative incidence analyses for DM, and secondarily, death with DM, were performed. Deaths without DM were treated as competing risks.

RESULTS

In the validation cohort (median follow-up, 17.2 years), LT-ADT significantly improved DM from 26% to 17% (subdistribution hazard ratio [sHR], 0.64 [95% CI, 0.50 to 0.82], P < .001). A significant biomarker-treatment predictive interaction was observed (P = .04) for DM, whereby MMAI biomarker???positive men (n = 785, 66%) had reduced DM with LT-ADT versus ST-ADT (sHR, 0.55 [95% CI, 0.41 to 0.73], P < .001), whereas no treatment benefit was observed for MMAI biomarker???negative men (n = 407; sHR, 1.06 [95% CI, 0.61 to 1.84], P = .84). The estimated 15-year DM risk difference between RT + LT-ADT and RT + ST-ADT was 14% in MMAI biomarker???positive men and 0% in MMAI biomarker???negative men. The MMAI biomarker was also prognostic for DM, irrespective of treatment (sHR, 2.35 [95% CI, 1.72 to 3.19], P < .001).

CONCLUSION

To our knowledge, the MMAI model is the first validated predictive biomarker to guide ADT duration with RT in localized/locally advanced PCa. Approximately one third of men with high-risk PCa could safely be spared the additional 24 months of ADT and the associated morbidity.

Author Affiliations

¹Duke University Medical Center, Durham, NC; ²Artera Inc, Los Altos, CA; ³University of California San Francisco, San Francisco, CA; ⁴Mayo Clinic, Rochester, MN; ⁵Cedars-Sinai Medical Center, Los Angeles, CA; ⁶University of Maryland, Baltimore, MD; ⁷Case Western Reserve University, Cleveland, OH; ⁸Saint John Regional Hospital, Saint John, New Brunswick, CA; ⁹Northeast Radiation Oncology Center, Dunmore, PA accrual for Regional Hospital of Scranton; ¹⁰Zablocki Veterans Administration Medical Center, Milwaukee, WI; ¹¹Medical College of Wisconsin, Milwaukee, WI, Accrual for Clarkson Hospital; ¹²Long Beach VA Healthcare System, Long Beach, CA; ¹³Saint Agnes Medical Center, Fresno, CA; ¹⁴Baptist Medical Center South, Jacksonville, FL; ¹⁵Saskatoon Cancer Centre, Saskatoon, SK; ¹⁶NRG Oncology Statistics and Data Management Center, Philadelphia, PA; ¹⁷American College of Radiology, Philadelphia, PA; ¹⁸University of California San Diego Moores Cancer Center, La Jolla, CA; ¹⁹University of Michigan, Ann Arbor, MI; ²⁰Brigham and Women's Hospital, Boston, MA

European Study of Prostate Cancer Screening — 23-Year Follow-up

A 13% reduction in mortality was observed in the screening group, with an improved harm-benefit ratio. For every 456 men screened, one prostate cancer death was prevented. It is an easy and inexpensive test, though concerns remain regarding unnecessary biopsies and overtreatment.

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Pasritamig was administered to patients who had received a median of four prior lines of systemic therapy. It was well tolerated, with manageable adverse events, making it suitable for outpatient administration. The treatment showed a median radiographic progression-free survival of 7.85 months, and 14 out of 33 participants achieved a ≥50% reduction in baseline PSA levels. So, stay tuned.

Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial

In patients with localized prostate cancer, predominantly low-risk and intermediate-risk disease, the long-term update reveals 13-year outcomes. Treatment failure occurred less frequently in men undergoing HIMRT (n = 13) compared with those undergoing CIMRT.

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

Another study showing the benefits of adding AR blocker to ADT. Improved PFs and suggestive improvement in OS, also less fatigue.

Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer

Less radiation is non-inferior, this is for low and intermediate-risk localized prostate cancer patients. Would like input from our radiation oncologists as to whether or not this adoptable?